Turbine, a company that uses cell simulations to guide biopharma R&D, announced that it has raised €5.5 million in additional Series A funding. The round, which was led by MassMutual Ventures (MMV), brings the total amount raised to €25.5 million.
The company will use the funds to advance its internal pipeline of simulation-guided programs while scaling its biology simulation platform to support additional partnerships.
“We are excited to announce this additional funding, which will allow us to accelerate our mission of bringing the right drug to every patient in need,” said Kristof Szalay, Ph.D., CEO and co-founder of Turbine. “Our cell simulations have the potential to revolutionize the way that biopharma R&D is conducted, and we are grateful to our investors for their continued support.”
Turbine’s cell simulations are based on a proprietary platform that can represent patient populations that existing biological models cannot. They also have the capacity to perform assays that would be impractical to conduct at scale and with high throughput. A proprietary closed-loop learning process validates promising hypotheses in Turbines in vitro and in vivo assays.
“Turbine’s platform has the potential to transform key aspects of the oncology drug discovery and development process,” said Anvesh Ramineni, Managing Partner at MMV. “We believe that Turbine is well-positioned to become a leader in this space, and we are excited to support the company’s growth.”
In addition to MMV, the additional Series A round was also supported by existing investors such as 43North, Casdin Capital, and the European Investment Fund.
About Turbine ( Turbine.ai )
Turbine is a London, UK-based company that uses cell simulations to guide biopharma R&D. The company’s platform can represent patient populations that existing biological models cannot, and it has the capacity to perform assays that would be impractical to conduct at scale and with high throughput. Turbine is supported by companies such as Bayer and MSD, and it has multiple in vivo validated novel assets in its proprietary and partnered pipeline.
Funding Datasheet for Turbine.Ai
| Company | Founders | Sector | Investors | Funding |
|---|---|---|---|---|
| Turbine | 1. Kristof Szalay, PhD 2. Daniel Veres, M.D., PhD. 3. Szabolcs Nagy 4. Ivan Fekete, M.D. | Biopharma | MassMutual Ventures, 43North, Casdin Capital, and the European Investment Fund | €25.5 million (Series A) |
The Problem that Turbine tackles
The traditional approach to drug discovery is a slow and expensive process. It can take years to identify a promising drug target, and even longer to develop a new drug. This is because biological systems are complex and difficult to model.
How Turbine.ai Solves the Problem
Turbine’s cell simulations provide a more efficient and accurate way to model biological systems. This allows the company to identify promising drug targets more quickly and to develop new drugs more effectively.
Turbine is a promising company that is using cell simulations to revolutionize the way that biopharma R&D is conducted. The company’s platform has the potential to significantly reduce the time and cost of drug discovery, and it could help to bring new and effective treatments to patients sooner.